Abstract: The present invention opens to the public a method to prepare a benzopyran compound and its use for treating pulmonary fibrosis. A benzopyran compound has a structure (I): in which: R1 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R2 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R3 represents hydrogen, or C1-C4 alkyl; and n is any integer of 1-4, wherein the benzopyran compound is derived from a broth of Streptomyces xiamenensis CGMCC No. 5675 by extraction, separation and purification. The derivatives of xiamenmycin made from the present invention have a higher bioactivity to suppress the proliferation of normal human lung fibroblast, and medicinal products containing the same are useful in the treatment of pulmonary fibrosis.

Abstract: The present invention involves the application of a gene cluster, and bacterial strains that used in the biosynthesis of Xiamenmycin. The nucleotide sequence of the gene cluster is showed as SEQ ID NO.1, with the whole length of 5189 base pairs. The present invention involves Streptomyces xiamenensis CGMCC No. 5670 and its mutant strain, and the method that how the mentioned bacterial strain produces Xiamenmycin. The present invention provides the strain sources by using Streptomyces xiamenensis, its mutant strains or genetically engineered microbial strains carrying the above-mentioned Xiamenmycin biosynthesis gene cluster for cultivation and produce benzopyran compound Xiamenmycin through biosynthesis. The mutant strains can be used in industrial production.

Abstract: The present invention involves the application of a gene cluster, and bacterial strains that used in the biosynthesis of Xiamenmycin. The nucleotide sequence of the gene cluster is showed as SEQ ID NO.1, with the whole length of 5189 base pairs. The present invention involves Streptomyces xiamenensis CGMCC No. 5670 and its mutant strain, and the method that how the mentioned bacterial strain produces Xiamenmycin. The present invention provides the strain sources by using Streptomyces xiamenensis, its mutant strains or genetically engineered microbial strains carring the above-mentioned Xiamenmycin biosynthesis gene cluster for cultivation and produce benzopyran compound Xiamenmycin through biosynthesis. The mutant strains can be used in industrial production.

Abstract: The present invention opens to the public a method to prepare a benzopyran compound and its use for treating pulmonary fibrosis. A benzopyran compound has a structure (I): in which: R1 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R2 represents hydrogen, C1-C4 alkyl, or various remaining amino acid moieties after removal of an amino group; R3 represents hydrogen, or C1-C4 alkyl; and n is any integer of 1-4, wherein the benzopyran compound is derived from a broth of Streptomyces xiamenensis CGMCC No. 5675 by extraction, separation and purification. The derivatives of xiamenmycin made from the present invention have a higher bioactivity to suppress the proliferation of normal human lung fibroblast, and medicinal products containing the same are useful in the treatment of pulmonary fibrosis.